Business Context and Reporting Period
Company: EUDA Health Holdings Ltd (EUDA)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: EUDA operates in two primary segments: Property Management Services and Holistic Wellness Consumer Products and Services. The company is a British Virgin Islands entity listed on Nasdaq (Ticker: EUDA). In September 2023, the company streamlined its medical service operations, classifying them as discontinued operations. In May 2024, it acquired CK Health to expand into wellness products and services, including bioenergy cabins and stem cell therapy facilitation.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $6.82 million | $4.01 million |
| Net Loss | $(2.77) million | $(15.39) million |
| Net Loss from Continuing Operations | $(2.77) million | $(17.64) million |
| Gross Profit | $2.99 million | $0.76 million |
| Operating Cash Flow | $(2.43) million | $(2.03) million |
| Cash and Cash Equivalents (Dec 31, 2025) | $0.35 million | $0.24 million |
| Working Capital Deficit | $(4.80) million | $(3.38) million |
| Ordinary Shares Outstanding | 1,890,375 | 1,857,653 |
Note: Share counts reflect retroactive effect of a 1-for-20 reverse stock split effected on March 23, 2026.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 70.0% to $6.82 million, driven primarily by the new Holistic Wellness segment which generated $2.45 million (29.3% of total revenue) compared to $0.09 million in 2024. Property Management revenue grew 11.4% to $4.37 million.
- Profitability Improvement: Net loss decreased significantly by 82.0% to $2.77 million. This improvement was largely due to the absence of a $14.76 million impairment loss on long-lived assets recorded in 2024 related to the Fortress Cove acquisition.
- Segment Performance: The Property Management segment returned to profitability with a segment profit of $0.15 million in 2025, compared to a loss of $0.19 million in 2024. The Holistic Wellness segment reduced its loss from $15.43 million to $1.03 million.
- Capital Structure: The company completed a 1-for-20 reverse stock split in March 2026. In February 2026, it raised $3.75 million through a private placement of 625,000 ordinary shares.
Guidance, Outlook, Risks, and Contingencies
Going Concern and Liquidity
The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern. The company has a working capital deficit of approximately $4.8 million and cash of only $0.35 million as of December 31, 2025. Management plans to address this through equity financing and loans from related parties, but there is no assurance of success.
Nasdaq Compliance
The company received a notice from Nasdaq on April 23, 2026, regarding failure to maintain the Minimum Market Value of Listed Securities (MVLS) of $35 million. The company has until October 20, 2026, to regain compliance or face delisting.
Internal Controls
Management identified a material weakness in internal control over financial reporting related to the lack of appropriate controls in the financial reporting process, specifically account reconciliations. This weakness was present in both 2024 and 2025.
Strategic Risks
- Stem Cell Therapy: The company relies on a third-party distributor (Key Lock) to sell stem cell therapies developed by Guangdong Cell Biotech in China. The agreement is terminable with one month's notice, and the company has no experience in this line of business.
- Utility Token: The company entered into an agreement to purchase 16 million QB Utility Tokens for a digital health platform. There is no assurance the platform will launch or that the tokens will generate expected benefits.
- Acquisition Integration: There is no assurance that the company will achieve the desired financial benefits from the acquisition of CK Health.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $3.75 million raised in February 2026 to cover the $4.8 million working capital deficit and ongoing operating losses.
- Nasdaq Compliance: Monitor the company's progress toward regaining MVLS compliance by the October 20, 2026 deadline to avoid delisting.
- Internal Control Remediation: Review the status of the remediation plan for the material weakness in internal controls over financial reporting.
- Third-Party Dependencies: Assess the stability of the collaboration agreement with Key Lock for stem cell therapies and the development status of the QB Utility Token platform.
- Related Party Transactions: Scrutinize the terms and repayment status of loans from related parties (e.g., 8i Enterprises Pte Ltd, Alfred Lim) which were significant sources of liquidity in 2025.